bioMerieux (OTCMKTS:BMXMF) Given Consensus Recommendation of “Reduce” by Analysts

Shares of bioMerieux (OTCMKTS:BMXMF) have been assigned an average rating of “Reduce” from the six brokerages that are covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell rating and four have assigned a hold rating to the company.

Several equities research analysts have commented on the stock. UBS Group lowered shares of bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Morgan Stanley downgraded bioMerieux from an “overweight” rating to an “underweight” rating in a research note on Tuesday, June 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Zacks Research lowered bioMerieux from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Finally, Piper Sandler assumed coverage on bioMerieux in a research report on Thursday, June 11th. They issued a “neutral” rating on the stock.

bioMerieux Price Performance

Shares of OTCMKTS:BMXMF opened at $82.66 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39. The stock’s fifty day simple moving average is $79.69 and its two-hundred day simple moving average is $94.08. bioMerieux has a 1-year low of $77.00 and a 1-year high of $152.00.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.